Antimicrob Agents Chemother.
2009;53:5300–2.PubMedCentralPubMedCrossRef 9. Jacqueline C, Caillon J, Le Mabecque Pitavastatin mouse V, et al. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrob Agents Chemother. 2007;51:3397–400.PubMedCentralPubMedCrossRef 10. Croisier-Bertin D, Piroth L, Charles PE, et al. Ceftaroline versus ceftriaxone in a highly penicillin-resistant pneumococcal LCZ696 solubility dmso pneumonia rabbit model using simulated human dosing. Antimicrob Agents Chemother. 2011;55:3557–63.PubMedCentralPubMedCrossRef 11. Talbot GH, Thye D, Das A, Ge Y. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure
infections. Antimicrob Agents Chemother. 2007;51:3612–6.PubMedCentralPubMedCrossRef 12. File TM Jr, Low DE, Eckburg PB, et al. FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011;66:iii19–32. 13. Low DE, File TM Jr, Eckburg PB, et al. FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety this website of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011;66:iii33–44. 14. Corey GR, Wilcox MH, Talbot GH, Thye D, Friedland D, Baculik T. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65(Suppl 4):iv41–51. 15. Wilcox MH, Corey GR, Talbot
GH, Thye D, Friedland D, Baculik T. CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65:iv53–65. 16. AstraZeneca press releases. European Commission approves ZINFORO™ (ceftaroline fosamil) for adult patients with serious skin infections or community acquired pneumonia. August 28, 2012 [January 29, 2013]. http://www.astrazeneca.com/Media/Press-releases/Article/28082012-european-commission-approves-zinforo. Protein tyrosine phosphatase (Accessed 8 March 2013). 17. Ishikawa T, Matsunaga N, Tawada H, Kuroda N, Nakayama Y, Ishibashi Y, Tomimoto M, Ikeda Y, Tagawa Y, Iizawa Y, Okonogi K, Hashiguchi S, Miyake A. TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties. Bioorg Med Chem. 2003;11:2427–37.PubMedCrossRef 18. Zapun A, Contreras-Martel C, Vernet T. Penicillin-binding proteins and beta-lactam resistance. FEMS Microbiol Rev. 2008;32:361–85.PubMedCrossRef 19. Kosowska-Shick K, McGhee PL, Appelbaum PC.